Übersetzung für "benefit risk ratio " (Englisch → Deutsch) :

— there is demonstration of equivalence of the functions, indications, benefit/risk ratio and therapeutic efficacy expected of the device to the device to which the data relates and,

It will be essential to swiftly assess additional data as they become available and to closely monitor for any unexpected serious adverse reactions to allow for reassessment of the risk-benefit ratio where necessary. Close cooperation between Member States, the EMEA and the ECDC, as well as post-marketing surveillance including pharmacovigilance and risk-management plans, are therefore important.

the potential for the sustainable use of pesticides to promote increased competitiveness in agriculture, forestry and horticulture in the European Union at the same time as reducing risks from pesticide use to human health and the environment; promoting low-pesticide input farming, including organic farming; the need to make the best possible use of existing Community procedures and to take into account the value of voluntary as well as mandatory measures so as to minimise administrative burden and therefore to maximise the positive cost-benefit ratio ...[+++] for the implementation of the Thematic Strategy; the fact that further measures of a diverse nature, including indicators and widening the strategy to cover biocides, should also be developed in order fully to achieve the objectives of the Thematic Strategy; the desirability of making the best use of existing Community financial instruments, in particular to develop integrated pest management methods and procedures;

"1a. The analysis of the benefit/risk ratio shall be deemed to be an initial step towards a study into the relative and/or real efficiency of a medicinal product".

This represents a very advantageous cost benefit ratio for those looking to get the highest profit with the lowest investment, easy and wide distribution and low risk of detection and penalty.

On 11 December 1991 the CPMP issued its opinion, which was against a total revocation of the marketing authorisations and requested the ad hoc rapporteurs' group appointed by the CPMP to supplement the work already done by assessing the relative risk-benefit ratios of all short-acting hypnotics, including Triazolam.